Management Team

Nick Spring, BSc (Hons), DipM, MCIM

Nick Spring, BSc (Hons), DipM, MCIM

Chief Executive Officer

  • Experienced executive with 35+ years of relevant experience in the life sciences industry
  • Founder of Humanitas Consulting and BioVeras Technologies
  • Former CEO and Founder of Topaz Pharmaceuticals Inc. (Acquired by Sanofi for $200+ million)
  • Former executive at Merck, Instrumental in building several billion-dollar franchises
  • Former CEO of Reliefband Technologies LLC and Partner, Life Sciences USA at Alten Calsoft

Steve King

Chief Operating Officer

Steve King

Steve King

Chief Operating Officer

  • Seasoned pharmaceutical industry leader with 35+ years of relevant experience
  • Worked on 500+ small molecule programs over his career, many from inception through to commercial launch
  • Current President of 21159Pharma, which focuses on Licensing and CMC drug development
  • Former Senior Vice President and Head of Business Development at Pii
  • Former experience working at Janssen (J&J company) and R P Scherer (Catalent)

Board of Directors

Dr. Jerome B. Zeldis, M.D., Ph.D.

Dr. Jerome B. Zeldis, M.D., Ph.D.

Director

Dr. Zeldis has served as Executive Chairman of ViralClear Pharmaceuticals since March of 2020 and has served on the board of BioSig Technologies since June of 2019. He previously served as Chief Medical Officer and President of Clinical Research, Medical Affairs Drug Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc. He attended Brown University for an AB, MS, followed by Yale University for an MPhil, MD, and Ph.D. in Molecular Biophysics and Biochemistry. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Dr. Zeldis is a named inventor on 43 US patents, has published 122 peer reviewed articles and 24 reviews, book chapters, and editorials.

Anthony Zook

Anthony Zook

Director

Mr. Zook is a proven leader in the field of pharmaceuticals and biotechnology. Through his career at AstraZeneca Plc [LON:AZN], he amassed a wealth of commercialization experience and held several executive positions, including Executive Vice President of Global Commercial Operations, President and Chief Executive Officer – North American division, and President of Medimmune, the company’s wholly-owned biologics division. Under his leadership, AstraZeneca commercialized ten blockbuster brands, each garnering over $1 billion in sales. Working alongside the CEO, CFO, and Head of R&D, Mr. Zook sat on the Portfolio Investment Board (PIB), which set and approved the overall strategy for Research and Development and allocated resources by therapeutic area.

Mr. Zook served or continues to serve on several boards, including the boards of AltheRx, Inhibikase, Rib-X Pharmaceuticals, the National Pharmaceutical Council, PhRMA, the Pennsylvania Division of the American Cancer Society and his alma mater, Frostburg State University.

Mr. Zook earned a B.S. degree from Frostburg State University and an A.A. degree in chemical engineering from Pennsylvania State University.

Dennis Purcell

Dennis Purcell

Director

Mr. Purcell is the Founder of Aisling Capital LLC and previously served as Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”). Aisling Capital (formerly Perseus-Soros Bio-pharmaceutical Fund), formed in 2001, is a leading venture capital fund that has invested over $2 billion in emerging biopharmaceutical companies globally which has helped the industry to mature and become the main source of new innovative drugs and devices being used to treat diseases today. While at H&Q, Mr. Purcell was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the Life Sciences industry. During his tenure, various industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell serves on numerous healthcare company boards.  He currently sits on the Boards of Real Endpoints, Summus Global, Inc., BioScience Managers Pty Ltd., and Ichnos Sciences. He also serves as a member of the Board of: the Editorial Advisory Board at Life Science Leader Magazine; the Executive Committee at NYBIO Association; the University of Delaware Investment Visiting Committee as well as the Biopharmaceutical Innovation Board at the University of Delaware; the Foundation of the Alliance for Regenerative Medicine; and the Healthcare sector of the New York City Investment Fund. He is also an Executive in Residence at Columbia University.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.

Michael Dougherty

Michael Dougherty

Director

Mr. Dougherty has over 30 years of experience in the pharmaceutical industry, most recently serving as Executive Chairman of Celator Pharmaceuticals, Inc. (sold to Jazz Pharmaceuticals). Prior to Celator, Mr. Dougherty served as Chief Executive Officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc.

Earlier in his career, Mr. Dougherty served in a number of roles during his ten-year tenure at Adolor Corporation, including President and Chief Executive Officer, member of the board of directors, Chief Operating Officer, and Chief Financial Officer. Prior to Adolor, Mr. Dougherty was President and Chief Operating Officer of Genomics Collaborative, Inc. He served in a variety of senior positions at Genaera Corporation, including President and Chief Executive Officer and member of the board of directors. Mr. Dougherty is currently serving on the board of directors at Idera Pharmaceuticals, Inc, Marinus Pharmaceuticals, Inc., Centocor, Inc., and Trevena, Inc. He previously served on the boards of Foundation Medicine, Inc., Celator Pharmaceuticals, Inc, Aviragen Therapeutics, Cempra, Inc., and Viropharma, Inc.

Mr. Dougherty received a bachelor’s degree in accounting from Villanova University.

Kenneth L. Londoner, MBA

Founder, Chief Executive Officer, Chairman, and Director

Kenneth L. Londoner, MBA

Kenneth L. Londoner, MBA

Founder, Chief Executive Officer, Chairman, and Director

Mr. Londoner is a capital markets and capital architecture expert and a senior life science executive. Having started his career as a research analyst for J. & W. Seligman & Co., Inc., a leading institutional money management firm in New York City, NY, he quickly found himself at the forefront of the biotech industry in the early 1990s, leading him to manage $3.5 billion in mutual and pension funds and international assets.

His passion for medical innovation led him to co-found, govern and bring to the public market a number of life science companies, including BioSig Technologies, Inc. [Nasdaq:BSGM]. Working in close collaboration with key opinion leaders in electrophysiology, BioSig aims to improve the outcomes of cardiac ablations for the treatment of arrhythmias through novel technological solutions developed by the company, and further apply its core competency in advanced biomedical signal processing and analysis to other areas of medicine.

His prior experience in recognizing the early potential of biotech led Londoner to form the Alliance for Advancing Bioelectronic Medicine, an independent non-profit network of professionals dedicated to innovation at the intersection of healthcare and technology. The Alliance aims to increase awareness of bioelectronic medicine and build a platform for collaboration among stakeholders. Over the last decade, Londoner formed top level relationships with a number of medical centers of excellence such as Mayo Clinic, NYU Langone Hospital and UCLA, as well as other stakeholders, including investment communities, intellectual property experts and supply chain partners.

Nick Spring, BSc (Hons), DipM, MCIM

Nick Spring, BSc (Hons), DipM, MCIM

Chief Executive Officer

  • Experienced executive with 35+ years of relevant experience in the life sciences industry
  • Founder of Humanitas Consulting and BioVeras Technologies
  • Former CEO and Founder of Topaz Pharmaceuticals Inc. (Acquired by Sanofi for $200+ million)
  • Former executive at Merck, Instrumental in building several billion-dollar franchises
  • Former CEO of Reliefband Technologies LLC and Partner, Life Sciences USA at Alten Calsoft